Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 112 clinical trials
Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer

This is a phase 2, single arm, open label trial to evaluate the rate of failure free survival at 2 years after start of chemoradiation with adjuvant nivolumab in adult subjects who undergo chemoradiation for localized bladder cancer.

transurethral resection
invasive bladder cancer
bladder cancer
bladder tumor
nivolumab
  • 70 views
  • 27 Jan, 2021
  • 1 location
Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer (ABATE)

This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy. Each cycle equals 21 days. The dose of atezolizumab is 1200 mg IV flat dose every 3 weeks …

transurethral resection
aptt
g-csf
invasive bladder cancer
gilbert's syndrome
  • 0 views
  • 28 Jan, 2021
  • 3 locations
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

invasive bladder cancer (NMIBC). All participants will receive an induction course of gemcitabine/docetaxel instillations followed by maintenance instillations if initial efficacy is seen. In addition to

transurethral resection
bcg vaccine
invasive bladder cancer
gemcitabine
bladder cancer
  • 0 views
  • 25 Jan, 2021
  • 1 location
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer

A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a marker tumour deliberately left following transurethral resection of multiple, papillary NMIBC tumours.

transurethral resection
bladder carcinoma
invasive bladder cancer
bladder cancer
carcinoma in situ
  • 1 views
  • 01 Feb, 2021
  • 1 location
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

This is a phase II trial to evaluate the tolerability, efficacy, and immune outcomes of AGEN1884 plus AGEN2034 concurrent with cisplatin and gemcitabine in the neoadjuvant treatment of muscle-invasive, non-metastatic bladder cancer prior to radical cystectomy.

invasive bladder cancer
gilbert's syndrome
gemcitabine
bladder cancer
conjugated bilirubin
  • 0 views
  • 26 Jan, 2021
  • 1 location
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

This pilot study is evaluating how well pembrolizumab and combination chemotherapy before surgery work for the treatment of specific types of muscle-invasive bladder cancer that have unusual

  • 0 views
  • 27 Jan, 2021
  • 1 location
Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

This is a phase II study of Paclitaxel-binding albumin, Cisplatin as neoadjuvant chemotherapy in patients with muscle-invasive urothelial carcinoma of the bladder. Patients with muscle invasive urothelial carcinoma who are candidates for radical cystectomy will be enrolled.

  • 0 views
  • 23 Jan, 2021
  • 1 location
Pembrolizumab (MK-3475) as First-line Therapy for High Risk T1 Non-Muscle-Invasive Bladder Cancer

The purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on the participant and urothelial cancer.

transurethral resection
lymphadenectomy
invasive bladder cancer
bladder cancer
carcinoma in situ
  • 18 views
  • 25 Jan, 2021
  • 8 locations
Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer

Disease recurrence and progression is a major issue in high risk non-muscle-invasive bladder cancer (NMIBC). The current study compares two adjuvant instillation therapies in the

bladder carcinoma
invasive bladder cancer
bladder cancer
carcinoma in situ
bladder tumor
  • 18 views
  • 23 Jan, 2021
  • 10 locations
Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

carcinoma and a cohort of patients with muscle invasive bladder cancer. Secondary 1A. To assess the proportion of patients who achieve pathological CR with daratumumab

metastatic renal cell carcinoma
metastasectomy
ovarian suppression
bladder cancer
gilbert's syndrome
  • 21 views
  • 22 Jan, 2021
  • 2 locations